Several pharmaceutical companies are working to find alternative drugs to treat COVID-19-associated mucormycosis in India amid concerns there might be a shortage of amphotericin B, reported Sputnik.

Celon Labs announced on Monday the launch of an emulsion formulation of amphotericin B.

The company will reportedly manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly, the news source said.

"The emulsion-based formulation is an ideal alternative to liposomal amphotericin B to combat the [mucormycosis]. The company will start supplying the domestic market soon," said managing director M. Nagesh Kumar.

Last week, Genetic Life Sciences started manufacturing amphotericin B emulsion injections priced at INR 1200 each.